PRESS RELEASE published on 09/23/2024 at 17:51, 1 year 7 months ago AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024 AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024, showing promising results in phase 2B/3 study AB07002 Phase 3 Study AB Science Masitinib ECTRIMS 2024 Progressive Multiple Sclerosis
BRIEF published on 07/08/2024 at 08:01, 1 year 10 months ago AB Science Announces Positive Results of Phase 2 Study for Masitinib in COVID-19 COVID-19 Clinical Trial Phase 2 Study AB Science Masitinib
BRIEF published on 07/08/2024 at 08:01, 1 year 10 months ago AB Science annonce les résultats positifs de l'étude de phase 2 sur le masitinib dans le traitement du COVID-19 Essai Clinique Étude De Phase 2 COVID 19 AB Science Masitinib
PRESS RELEASE published on 07/08/2024 at 07:56, 1 year 10 months ago AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19 AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment COVID-19 Treatment Phase 2 Study AB Science Masitinib
PRESS RELEASE published on 07/08/2024 at 07:56, 1 year 10 months ago AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19 AB Science annonce des résultats positifs de son étude de phase 2 évaluant le masitinib dans la COVID-19. Les analyses montrent un potentiel traitement prometteur pour les patients hospitalisés COVID-19 Traitement Étude De Phase 2 AB Science Masitinib
BRIEF published on 06/28/2024 at 12:36, 1 year 10 months ago AB Science fait le point sur la demande d'autorisation du masitinib dans la SLA Autorisation De Mise Sur Le Marché AB Science Masitinib EMA SLA
BRIEF published on 06/28/2024 at 12:36, 1 year 10 months ago AB Science provides an update on the application for authorization of masitinib in ALS ALS AB Science Masitinib EMA Marketing Authorization
PRESS RELEASE published on 06/28/2024 at 12:31, 1 year 10 months ago AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA AB Science annonce un avis négatif sur la demande de mise sur le marché du masitinib dans la SLA et prévoit un réexamen du dossier. Détails sur les raisons et les prochaines étapes AB Science Masitinib Sclérose Latérale Amyotrophique Autorisation Conditionnelle Réexamen Dossier
PRESS RELEASE published on 06/28/2024 at 12:31, 1 year 10 months ago AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations AB Science Masitinib CHMP ALS Treatment Conditional Marketing Authorization
BRIEF published on 06/27/2024 at 10:20, 1 year 10 months ago AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024 Actionnaires Capital Social Assemblée Générale Resolutions AB Science
Published on 05/21/2026 at 15:00, 2 hours 2 minutes ago Karbon-X Expands Global Energy Attribute Certificate Market Capabilities Amid Growing Renewable Procurement Demand
Published on 05/21/2026 at 14:30, 2 hours 32 minutes ago Rio Grande Resources Advances District-Scale Gold-Silver Target Definition at its Winston Project Through Structural Mapping of Multiple Vein Corridor Systems
Published on 05/21/2026 at 14:00, 3 hours 2 minutes ago Nextech3d.ai to Showcase AI Event Operating System and Krafty Labs Marketplace at Leading EMRG Media Event in New York
Published on 05/21/2026 at 14:00, 3 hours 2 minutes ago Jade Leader Reviews Its Available Critical Minerals Assets
Published on 05/21/2026 at 14:00, 3 hours 2 minutes ago Horizon Aircraft Advances Dual-Use Certification Path Through Cert Center Canada Partnership
Published on 05/21/2026 at 16:45, 16 minutes ago tonies SE - Invitation to Capital Markets Day 2026 (June 18, London)
Published on 05/21/2026 at 16:05, 56 minutes ago Omio expands white-label network with new TUI partnership
Published on 05/21/2026 at 15:43, 1 hour 18 minutes ago Annual General Meeting approves all proposed resolutions and renews authorization for share buyback – Dividend of EUR 0.65 approved
Published on 05/21/2026 at 15:30, 1 hour 31 minutes ago PATRIMOINE ET COMMERCE: ASSEMBLEE GENERALE MIXTE DU 11 JUIN 2026 - MODALITE DE MISE A DISPOSITION ET DE CONSULTATION DES DOCUMENTS PREPARATOIRES A L’ASSEMBLEE
Published on 05/21/2026 at 16:35, 26 minutes ago 260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026
Published on 05/21/2026 at 07:30, 9 hours 32 minutes ago Biophytis participe au premier Sommet de la Longévité
Published on 05/21/2026 at 07:30, 9 hours 32 minutes ago Biophytis participates in the first Longevity Summit
Published on 05/20/2026 at 18:00, 23 hours 2 minutes ago General shareholders meeting of 20 May, 2026
Published on 05/20/2026 at 18:00, 23 hours 2 minutes ago General shareholders meeting of 20 May, 2026